Literature DB >> 21934093

A functional variant at the miR-184 binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck.

Zhensheng Liu1, Sheng Wei, Hongxia Ma, Mei Zhao, Jeffrey N Myers, Randal S Weber, Erich M Sturgis, Qingyi Wei.   

Abstract

Although the role of TNFAIP2 is still unclear, it is an important gene involved in apoptosis, and there are single-nucleotide polymorphisms (SNPs) at its microRNA (miRNA)-binding sites that could modulate miRNA target gene function. In this study, we evaluated associations of four selected SNPs (rs8126 T > C, rs710100 G > A, rs1052912 G > A and rs1052823 G > T) in the miRNA-binding sites of the 3' untranslated region (UTR) with squamous cell carcinoma of the head and neck (SCCHN) risk in 1077 patients with SCCHN and 1073 cancer-free controls in a non-Hispanic White population. We found that, compared with the rs8126 TT genotype, the variant C allele were associated with increased SCCHN risk in an allele dose-response manner (adjusted odds ratio = 1.48 and 95% confidence interval = 1.06-2.05 for CC, respectively; P(trend) = 0.009). No significant associations were seen for the other three SNPs (rs710100 G > A, rs1052912 G > A and rs1052823 G > T). Additionally, we identified that the rs8126 T > C SNP is within the miR-184 seed binding region in the 3' UTR of TNFAIP2. Further functional analyses showed that the rs8126 variant C allele led to significantly lower luciferase activity, compared with the T allele. In the genotype-phenotype correlation analysis of peripheral blood mononuclear cells from 64 SCCHN patients, the rs8126 CC genotype was associated with reduced expression of TNFAIP2 messenger RNA. Taken together, these findings indicate that the miR-184 binding site SNP (rs8126 T > C) in the 3' UTR of TNFAIP2 is functional by modulating TNFAIP2 expression and contributes to SCCHN susceptibility. Larger replication studies are needed to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21934093      PMCID: PMC3204352          DOI: 10.1093/carcin/bgr209

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  41 in total

1.  A QuikChange-like method to realize efficient blunt-ended DNA directional cloning and site-directed mutagenesis simultaneously.

Authors:  Yingfeng An; Anguo Lv; Wenfang Wu
Journal:  Biochem Biophys Res Commun       Date:  2010-05-13       Impact factor: 3.575

2.  An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset.

Authors:  Fengju Song; Hong Zheng; Ben Liu; Sheng Wei; Hongji Dai; Lina Zhang; George A Calin; Xishan Hao; Qingyi Wei; Wei Zhang; Kexin Chen
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

Review 3.  MicroRNAs in cancer - from research to therapy.

Authors:  William C S Cho
Journal:  Biochim Biophys Acta       Date:  2009-11-18

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 5.  MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy.

Authors:  William C S Cho
Journal:  Int J Biochem Cell Biol       Date:  2009-12-22       Impact factor: 5.085

6.  The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck.

Authors:  Chunying Li; Jiachun Lu; Zhensheng Liu; Li-E Wang; Hui Zhao; Adel K El-Naggar; Erich M Sturgis; Qingyi Wei
Journal:  Cancer Prev Res (Phila)       Date:  2010-01-19

7.  MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2.

Authors:  Niamh H Foley; Isabella M Bray; Amanda Tivnan; Kenneth Bryan; Derek M Murphy; Patrick G Buckley; Jacqueline Ryan; Anne O'Meara; Maureen O'Sullivan; Raymond L Stallings
Journal:  Mol Cancer       Date:  2010-04-21       Impact factor: 27.401

8.  A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.

Authors:  Brock C Christensen; Benjamin J Moyer; Michele Avissar; Lauren G Ouellet; Silvia L Plaza; Michael D McClean; Carmen J Marsit; Karl T Kelsey
Journal:  Carcinogenesis       Date:  2009-04-20       Impact factor: 4.944

9.  RhoB induces apoptosis via direct interaction with TNFAIP1 in HeLa cells.

Authors:  Dong-Myung Kim; Kyung-Sook Chung; Shin-Jung Choi; Yu-Jin Jung; Song-Kyu Park; Gyoon-Hee Han; Jae-Seok Ha; Kyung-Bin Song; Nam-Song Choi; Hwan-Mook Kim; Misun Won; Yeon-Soo Seo
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

10.  MicroRNA alterations in head and neck squamous cell carcinoma.

Authors:  Steven S Chang; Wei Wen Jiang; Ian Smith; Luana M Poeta; Shahnaz Begum; Chad Glazer; Shannon Shan; William Westra; David Sidransky; Joseph A Califano
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

View more
  33 in total

1.  Identification of prohibitin and prohibiton as novel factors binding to the p53 induced gene 3 (PIG3) promoter (TGYCC)(15) motif.

Authors:  Xiaoxiang Guan; Zhensheng Liu; Luo Wang; David G Johnson; Qingyi Wei
Journal:  Biochem Biophys Res Commun       Date:  2014-01-03       Impact factor: 3.575

Review 2.  Levels of MicroRNA Heterogeneity in Cancer Biology.

Authors:  Nina Petrovic; Sercan Ergün; Esma R Isenovic
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

3.  Associations between expression levels of nucleotide excision repair proteins in lymphoblastoid cells and risk of squamous cell carcinoma of the head and neck.

Authors:  Peng Han; Hongliang Liu; Qiong Shi; Zhensheng Liu; Jesse D Troy; Walter T Lee; Jose P Zevallos; Guojun Li; Erich M Sturgis; Qingyi Wei
Journal:  Mol Carcinog       Date:  2018-03-25       Impact factor: 4.784

4.  A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer.

Authors:  Xiaoxiang Guan; Zhensheng Liu; Hongliang Liu; Hongping Yu; Li-E Wang; Erich M Sturgis; Guojun Li; Qingyi Wei
Journal:  FASEB J       Date:  2012-12-27       Impact factor: 5.191

5.  A variant at a potentially functional microRNA-binding site in BRIP1 was associated with risk of squamous cell carcinoma of the head and neck.

Authors:  Hongliang Liu; Fengqin Gao; Kristina R Dahlstrom; Guojun Li; Erich M Sturgis; Jose P Zevallos; Qingyi Wei; Zhensheng Liu
Journal:  Tumour Biol       Date:  2015-12-28

6.  The chaperone ERp29 is required for tunneling nanotube formation by stabilizing MSec.

Authors:  Rajaiah Pergu; Sunayana Dagar; Harsh Kumar; Rajesh Kumar; Jayanta Bhattacharya; Sivaram V S Mylavarapu
Journal:  J Biol Chem       Date:  2019-03-15       Impact factor: 5.157

7.  Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ≤ 55 years.

Authors:  Xiaoxiang Guan; Hongliang Liu; Jingfang Ju; Yangkai Li; Peng Li; Li-E Wang; Abenaa M Brewster; Thomas A Buchholz; Banu K Arun; Qingyi Wei; Zhensheng Liu
Journal:  Mol Carcinog       Date:  2013-10-26       Impact factor: 4.784

8.  Association between single nucleotide polymorphisms in ERCC4 and risk of squamous cell carcinoma of the head and neck.

Authors:  Hongping Yu; Zhensheng Liu; Yu-Jing Huang; Ming Yin; Li-E Wang; Qingyi Wei
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

9.  The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer.

Authors:  Yu Xu; Hongxia Ma; Hongping Yu; Zhensheng Liu; Li-E Wang; Dongfeng Tan; Ramya Muddasani; Victoria Lu; Jaffer A Ajani; Yanong Wang; Qingyi Wei
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

10.  A pri-miR-218 variant and risk of cervical carcinoma in Chinese women.

Authors:  Ting-Yan Shi; Xiao-Jun Chen; Mei-Ling Zhu; Meng-Yun Wang; Jing He; Ke-Da Yu; Zhi-Ming Shao; Meng-Hong Sun; Xiao-Yan Zhou; Xi Cheng; Xiaohua Wu; Qingyi Wei
Journal:  BMC Cancer       Date:  2013-01-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.